EP4157345A4 - GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF - Google Patents

GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF Download PDF

Info

Publication number
EP4157345A4
EP4157345A4 EP21811955.0A EP21811955A EP4157345A4 EP 4157345 A4 EP4157345 A4 EP 4157345A4 EP 21811955 A EP21811955 A EP 21811955A EP 4157345 A4 EP4157345 A4 EP 4157345A4
Authority
EP
European Patent Office
Prior art keywords
manipulated
protein
methods
coronavirus spike
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21811955.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4157345A2 (en
Inventor
Jason MCLELLAN
Jennifer MAYNARD
Andrea CHASSE
Ilya FINKELSTEIN
Mohammad JAVANMARDI
Jeffrey SCHAUB
Hung-Che KUO
Chia-Wei Chou
Jory GOLDSMITH
Christy HJORTH
Ching-Lin Hsieh
Patrick Byrne
Nicole Johnson
Nianshuang WANG
Daniel WRAPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
University of Texas System
University of Texas at Austin
Original Assignee
Dartmouth College
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College, University of Texas System, University of Texas at Austin filed Critical Dartmouth College
Publication of EP4157345A2 publication Critical patent/EP4157345A2/en
Publication of EP4157345A4 publication Critical patent/EP4157345A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21811955.0A 2020-05-29 2021-05-28 GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF Pending EP4157345A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032502P 2020-05-29 2020-05-29
PCT/US2021/034713 WO2021243122A2 (en) 2020-05-29 2021-05-28 Engineered coronavirus spike (s) protein and methods of use thereof

Publications (2)

Publication Number Publication Date
EP4157345A2 EP4157345A2 (en) 2023-04-05
EP4157345A4 true EP4157345A4 (en) 2024-09-11

Family

ID=78722816

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21811955.0A Pending EP4157345A4 (en) 2020-05-29 2021-05-28 GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF

Country Status (10)

Country Link
EP (1) EP4157345A4 (https=)
JP (1) JP2023527556A (https=)
KR (1) KR20230018394A (https=)
CN (1) CN116802193A (https=)
AU (1) AU2021279079A1 (https=)
BR (1) BR112022023591A2 (https=)
CA (1) CA3180554A1 (https=)
IL (1) IL298131A (https=)
MX (1) MX2022015040A (https=)
WO (1) WO2021243122A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323782B2 (en) 2011-10-12 2017-04-06 Vaxxas Pty Limited Delivery device
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2023067193A2 (en) 2021-10-22 2023-04-27 BioNTech SE Compositions for administration of different doses of rna
US20250122546A1 (en) 2021-10-28 2025-04-17 BioNTech SE Rna constructs and uses thereof
AU2022398292A1 (en) 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
WO2023147091A1 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
WO2023196634A2 (en) * 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
EP4670167A1 (en) 2023-02-24 2025-12-31 BioNTech SE Systems and methods for modifying synthetic antigens to promote personalized immune responses
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
WO2024243641A1 (en) * 2023-06-02 2024-12-05 Vaxxas Pty Limited Covid vaccine delivered by hd-map
WO2024249848A2 (en) * 2023-06-02 2024-12-05 The Scripps Research Institute Coronavirus s2 immunogens
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025179238A2 (en) 2024-02-23 2025-08-28 BioNTech SE Coronavirus vaccine
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970398A1 (en) * 2013-03-13 2016-01-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
WO2017037196A1 (en) * 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
EP3532095A1 (en) * 2016-10-25 2019-09-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Prefusion coronavirus spike proteins and their use
WO2020028902A1 (en) * 2018-08-03 2020-02-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nipah virus immunogens and their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970398A1 (en) * 2013-03-13 2016-01-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
WO2017037196A1 (en) * 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
EP3532095A1 (en) * 2016-10-25 2019-09-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Prefusion coronavirus spike proteins and their use
WO2020028902A1 (en) * 2018-08-03 2020-02-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nipah virus immunogens and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN YU ET AL: "Emerging coronaviruses: Genome structure, replication, and pathogenesis", JOURNAL OF MEDICAL VIROLOGY, vol. 92, no. 4, 7 February 2020 (2020-02-07), US, pages 418 - 423, XP055865868, ISSN: 0146-6615, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.25681> DOI: 10.1002/jmv.25681 *
JESPER PALLESEN ET AL: "Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 114, no. 35, 14 August 2017 (2017-08-14), pages E7348 - E7357, XP055692891, ISSN: 0027-8424, DOI: 10.1073/pnas.1707304114 *
KRARUP A ET AL: "A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 6, 3 September 2015 (2015-09-03), pages 8143 - 1, XP002755858, ISSN: 2041-1723, [retrieved on 20150903], DOI: 10.1038/NCOMMS9143 *

Also Published As

Publication number Publication date
KR20230018394A (ko) 2023-02-07
JP2023527556A (ja) 2023-06-29
IL298131A (en) 2023-01-01
AU2021279079A1 (en) 2022-12-15
CN116802193A (zh) 2023-09-22
EP4157345A2 (en) 2023-04-05
CA3180554A1 (en) 2021-12-02
WO2021243122A3 (en) 2022-02-10
WO2021243122A2 (en) 2021-12-02
US20230242594A1 (en) 2023-08-03
BR112022023591A2 (pt) 2022-12-27
MX2022015040A (es) 2023-02-27
WO2021243122A8 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
EP4157345A4 (en) GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF
EP4412606A4 (en) PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
EP4225373A4 (en) ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
EP4192863A4 (en) IL2RG BINDING MOLECULES AND METHODS OF USE
EP4090685A4 (en) ANTI-GAL3 ANTIBODIES AND METHODS OF USE
EP4330251A4 (en) EGFR DEGRADING AGENTS AND METHODS OF USE THEREOF
EP4208548A4 (en) DUX4 INHIBITORS AND METHODS OF USE
EP4444875A4 (en) MODIFIED CAS12B EFFECTOR PROTEINS AND METHODS OF USE THEREOF
EP4413147A4 (en) CAPSID VARIANTS AND METHODS OF USE THEREOF
EP4192852A4 (en) IL10RA-BINDING MOLECULES AND METHODS OF USE
EP4274603A4 (en) DNA NUCLEASE-GUIDED TRANSPOSASE COMPOSITIONS AND METHODS OF USE THEREOF
EP4329804A4 (en) Anti-gal3 antibody formulations and methods of use thereof
EP4228400A4 (en) PORCINE SEXED SEMEN AND METHODS OF USE
EP4486882A4 (en) MODIFIED NUCLEASES, COMPOSITIONS AND METHODS OF USE THEREOF
EP3927267A4 (en) PERIPHERAL VESSEL TISSUE MODIFICATION DEVICES AND METHODS OF USE THEREOF
EP4110317A4 (en) Kcnt1 inhibitors and methods of use
EP4243848A4 (en) MODIFIED VIRAL CAPSIDS AND METHODS OF USE
EP4399196A4 (en) PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
EP4228650A4 (en) INHALATED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF
EP4308097A4 (en) NON-HYDROXAMATE HDAC6 INHIBITORS AND METHODS OF USE THEREOF
EP4175981A4 (en) ANTI-CTLA-4 BINDING PROTEINS AND METHODS OF USE
EP4423081A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
EP4466346A4 (en) EFFECTIVE PROTEINS AND METHODS OF USE
EP4399524A4 (en) PHOSPHO-TAU ANTIBODIES AND METHODS OF USE
EP4408870A4 (en) INTERLEUKIN P40 SUBUNIT PROTEINS AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221220

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089187

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20240808

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/005 20060101ALI20240802BHEP

Ipc: C07K 14/165 20060101ALI20240802BHEP

Ipc: A61K 39/12 20060101AFI20240802BHEP